The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
Open accessAbstract
Purpose: To describe outcomes of prospective trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC). Patients and Methods: Two trials of SBRT for patients with active HCC unsuitable for standard locoregional therapies were conducted from 2004 to 2010. All patients had Child-Turcotte-Pugh class A disease, with at least 700 mL of non-HCC liver. The SBRT dose range was 24 to 54 Gy in six fractions. Primary end points were toxicity and local control at 1 year (LC1y), defined as no progressive disease (PD) of irradiated HCC by RECIST (Response Evaluation Criteria in Solid Tumors). Results: A total of 102 patients were evaluable (Trial 1, 2004 to 2007: n = 50; Trial 2, 2007 to 2010: n = 52). Underlying liver disease was hepatitis B in 38% of patients, hepatitis C in 38%, alcohol related in 25%, other in 14%, and none in 7%. Fifty-two percent received prior therapies (no prior sorafenib). TNM stage was III in 66%, and 61% had multiple lesions. Median gross tumor volume was 117.0 mL (range, 1.3 to 1,913.4 mL). Tumor vascular thrombosis (TVT) was present in 55%, and extrahepatic disease was present in 12%. LC1y was 87% (95% CI, 78% to 93%). SBRT dose (hazard ratio [HR] = 0.96; P = .02) and being in Trial 2 (HR = 0.38; P = .03) were associated with LC1y on univariate analysis. Toxicity ≥ grade 3 was seen in 30% of patients. In seven patients (two with TVT PD), death was possibly related to treatment (1.1 to 7.7 months after SBRT). Median overall survival was 17.0 months (95% CI, 10.4 to 21.3 months), for which only TVT (HR = 2.47; P = .01) and being in Trial 2 (HR = 0.49; P = .01) were significant on multivariate analysis. Conclusion: These results provide strong rationale for studying SBRT for HCC in a randomized trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
Venook, A. P., Papandreou, C., Furuse, J., & Ladrón de Guevara, L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s4-05 · Cited by 965
Kohler, B. A., Ward, E., McCarthy, B. J., Schymura, M. J., Ries, L. A. G., Eheman, C., Jemal, A., Anderson, R. N., Ajani, U. A., & Edwards, B. K. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr077 · Cited by 713
Tse, R. V., Hawkins, M., Lockwood, G., Kim, J. J., Cummings, B., Knox, J., Sherman, M., & Dawson, L. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3529 · Cited by 589
Self-citation(2000) · Hepatology · doi:10.1053/he.2000.5628 · Cited by 521
Méndez Romero, A., Wunderink, W., Hussain, S. M., De Pooter, J. A., Heijmen, B. J. M., Nowak, P. C. J. M., Nuyttens, J. J., Brandwijk, R. P., Verhoef, C., Ijzermans, J. N. M., et al. (2006) · Acta Oncologica · doi:10.1080/02841860600897934 · Cited by 498
Abou-Alfa, G. K., Johnson, P., Knox, J. J., Capanu, M., Davidenko, I., Lacava, J., Leung, T., Gansukh, B., & Saltz, L. B. (2010) · JAMA · doi:10.1001/jama.2010.1672 · Cited by 448
Self-citationStereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma
Andolino, D. L., Johnson, C. S., Maluccio, M., Kwo, P., Tector, A. J., Zook, J., Johnstone, P. A. S., & Cardenes, H. R. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.04.011 · Cited by 442
Kang, J., Kim, M., Cho, C. K., Yang, K. M., Yoo, H. J., Kim, J. H., Bae, S. H., Jung, D. H., Kim, Lee, D. H., et al. (2012) · Cancer · doi:10.1002/cncr.27533 · Cited by 334
Self-citationCárdenes, H. R., Price, T. R., Perkins, S. M., Maluccio, M., Kwo, P., Breen, T. E., Henderson, M. A., Schefter, T. E., Tudor, K., Deluca, J., et al. (2010) · Clinical and Translational Oncology · doi:10.1007/s12094-010-0492-x · Cited by 307
Stereotactic radiotherapy of primary liver cancer and hepatic metastases
Wulf, J., Guckenberger, M., Haedinger, U., Oppitz, U., Mueller, G., Baier, K., & Flentje, M. (2006) · Acta Oncologica · doi:10.1080/02841860600904821 · Cited by 271
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Oliveri, R. S., Wetterslev, J., & Gluud, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004787.pub2 · Cited by 268
Radiation therapy for hepatocellular carcinoma: From palliation to cure
Hawkins, M. A., & Dawson, L. A. (2006) · Cancer · doi:10.1002/cncr.21811 · Cited by 241
Self-citationYoon, S. M., Lim, Y.-S., Won, H. J., Kim, J. H., Kim, K. M., Lee, H. C., Chung, Y.-H., Lee, Y. S., Lee, S. G., Park, J.-H., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.03.019 · Cited by 223
Self-citationSon, S. H., Choi, B. O., Ryu, M. R., Kang, Y. N., Jang, J., Bae, S. H., Yoon, S. K., Choi, I. B., Kang, K. M., & Jang, H. S. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.009 · Cited by 151
Meng, M., Cui, Y., Lü, Y., She, B., Chen, Y., Guan, Y., & Zhang, R. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.11.002 · Cited by 143
Radiation Therapy for Hepatocellular Carcinoma
Feng, M. U.-S., & Ben‐Josef, E. (2011) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.05.002 · Cited by 104
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Wahl, D. R., Stenmark, M. H., Tao, Y., Pollom, E. L., Caoili, E. M., Lawrence, T. S., Schipper, M. J., & Feng, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4925 · Cited by 567
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Metadata
- Authors
- Bujold, A., Massey, C. A., Kim, J. J., Brierley, J., Cho, C., Wong, R. K. S., Dinniwell, R. E., Kassam, Z., Ringash, J., Cummings, B., Sykes, J., Sherman, M., Knox, J. J., & Dawson, L. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-05-01
- Volume
- 31
- Issue
- 13
- Pages
- 1631-1639
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133685049
- Cited by
- 820
- References
- 25
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.